AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented plasmid based technology that launches self-amplifying live attenuated viruses inducing a vigorous and polyfunctional immune response. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. AstriVax will focus on bringing their thermostable yellow fever, rabies and cHBV vaccine to the clinical development stage, thus clinically validating the platform technology for prophylactic and therapeutic use. The company is located in the BioHub in Leuven.
Website
Website
Location: Belgium, Flemish Brabant, Heverlee
Total raised: $32.62M
Investors 4
| Date | Name | Website |
| - | Fund+ | fundplus.b... |
| 31.08.2022 | V-Bio Vent... | v-bio.vent... |
| 01.09.2022 | Korys | korys.be |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.05.2023 | Grant | $2.68M | - |
| 25.08.2022 | Seed | $29.94M | - |
Mentions in press and media 7
| Date | Title | Description |
| 07.01.2025 | The next wave of innovation: 10 promising Belgian startups to keep an eye on in 2025 | The startup ecosystem in Belgium is very mature, signs are the increasing size of funding rounds, growing international investor participation, and frequent unicorns. A strong support network of incubators, accelerators, and venture funds b... |
| 12.12.2023 | AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine | - |
| 30.05.2023 | AstriVax Receives €2.5M Grant | AstriVax, a Leuven, Belgium-based provider of a plug-and-play vaccine platform, received a grant of €2.5M. The government grant was awarded by Flanders Innovation & Entrepreneurship (VLAIO). The company intends to use the funds to advan... |
| 26.09.2022 | Dr Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax | |
| 25.08.2022 | AstriVax Raises €30M in Seed Funding | Hanne Callewaert, PhD – portrait by Philippe Swiggers AstriVax, a Leuven, Belgium-based KU Leuven spin-off that develops vaccines, raised €30m in seed funding. The round was led by V-Bio Ventures and Fund+. The other investors are Flanders ... |
| 25.08.2022 | KU Leuven spin-off AstriVax raises € 30 million seed capital to build vaccine platform | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of spin-offs linked to Belgium-based university KU Leuven.The funding r... |
| 25.08.2022 | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform | KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform |